The FOLFOX study also demonstrated an improvement in treatment outcomes.[22] Positive response increased from 46% in the BSA-dosed group to 70% in the dose-adjusted group.  Median progression free survival (PFS) and overall survival (OS) both improved by six months in the dose adjusted group.[22]